bevacizumab + disitamab vedotin

Bevacizumab + disitamab vedotin is a combination therapy consisting of two distinct agents: - **Bevacizumab** is a recombinant humanized monoclonal antibody that targets and inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) essential for tumor growth. - **Disitamab vedotin** (RC48) is an antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody (hertuzumab) linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable linker. It binds to HER2-expressing tumor cells and delivers MMAE intracellularly to induce cell cycle arrest and apoptosis. This combination has been investigated primarily in patients with HER2-positive cancers such as metastatic breast cancer with brain or liver metastases. The rationale for combining these drugs lies in their complementary mechanisms—targeting both tumor vasculature and HER2-expressing cancer cells—which may enhance antitumor efficacy and overcome resistance seen with single-agent therapies[1][3]. Early clinical evidence suggests this regimen can achieve partial responses in heavily pretreated patients with manageable toxicity profiles[1][3].

Brand names

Avastin

Other names

bevacizumab + RC48bevacizumab + Aidixi